Cite
APA Citation
Genovese, M., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S., Koch, A., Cardillo, T., Rooney, T., Macias, W., Schlichting, D., & Smolen, J. (n.d.). oP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study. Annals of the rheumatic diseases, 74, 75–76. http://access.bl.uk/ark:/81055/vdc_100135135105.0x00005e